Researchers in the United States and Canada are launching a clinical trial to assess whether an analysis of the activity of certain genes associated with risk of recurrence for women with early-stage breast cancer can be used to determine appropriate treatments for patients (http://www.cancer.gov/clinicaltrials/digestpage/TAILORx).
The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, sponsored by the National Cancer Institute and coordinated by the Eastern Cooperative Oncology Group, is taking place at 900 sites in the United States and Canada. Researchers will enroll more than 10 000 women recently diagnosed with breast cancer that is estrogen receptor– and/or progesterone receptor–positive, Her2/neu-negative, and that has not spread to the lymph nodes.
Hampton T. Breast Cancer Trial. JAMA. 2006;295(24):2839. doi:10.1001/jama.295.24.2839-c